Vertaling van "core net income attributable to shareholders " (Nederlands → Frans) :

Financial income 14 91 Interest expenses -175 -136 Taxes (adjusted for above items) -643 -488 Core net income 2 771 2 394 Core net income attributable to shareholders 2 751 2 385
Produits financiers 14 91 Charges d’intérêts -175 -136 Impôts (ajustés des éléments ci-dessus) -643 -488 Résultat net « core » 2 771 2 394 Résultat net core attribuable aux actionnaires 2 751 2 385

Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG nm - not meaningful
Le résultat par action (BPA) est calculé sur la base du résultat net attribuable aux actionnaires de Novartis AG. ns: non significatif

1 Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG
Résultat net total 2 112 2 101 11 1 Attribuable aux: Actionnaires de Novartis AG 2 098 2 090 8 0

Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG
Le résultat par action (BPA) est calculé sur la base du résultat net attribuable aux actionnaires de Novartis AG.

Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.
Le résultat par action est calculé sur le résultat net attribuable aux actionnaires de Novartis AG.

2 Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG
Le résultat par action (BPA) est calculé sur la base du résultat net attribuable aux actionnaires de Novartis AG.

6 Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.
6 Le résultat par action (BPA) est calculé sur la base du résultat net attribuable aux actionnaires de Novartis AG.

31-okt-2013 Bayer continues positive business momentum Ongoing dynamic trend in Life Sciences; MaterialScience level with prior-year quarter / New pharmaceutical products post excellent growth / Group sales EUR 9,643 million (minus 0.2 percent; Fx & portfolio adj. plus 6.0 percent) / EBIT shows 47.5 percent improvement to EUR 1,221 million / EBITDA before special items moves 7.7 percent higher to EUR 1,984 million / Net income advances by 42.1 percent to EUR 733 million / Core earnings per share up 8.5 percent to EUR 1.27 / Group guidance for 2013 maintained » meer
31-oct.-2013 Bayer continues positive business momentum Ongoing dynamic trend in Life Sciences; MaterialScience level with prior-year quarter / New pharmaceutical products post excellent growth / Group sales EUR 9,643 million (minus 0.2 percent; Fx & portfolio adj. plus 6.0 percent) / EBIT shows 47.5 percent improvement to EUR 1,221 million / EBITDA before special items moves 7.7 percent higher to EUR 1,984 million / Net income advances by 42.1 percent to EUR 733 million / Core earnings per share up 8.5 percent to EUR 1.27 / Group guidance for 2013 maintained » En savoir plus